Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBT (2020 - 2025)

Janux Therapeutics (JANX) has disclosed EBT for 6 consecutive years, with -$31.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 58.02% to -$31.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$113.6 million through Dec 2025, down 64.69% year-over-year, with the annual reading at -$113.6 million for FY2025, 64.69% down from the prior year.
  • EBT for Q4 2025 was -$31.9 million at Janux Therapeutics, down from -$24.3 million in the prior quarter.
  • The five-year high for EBT was -$2.3 million in Q1 2021, with the low at -$33.9 million in Q2 2025.
  • Average EBT over 5 years is -$16.8 million, with a median of -$16.4 million recorded in 2022.
  • The sharpest move saw EBT tumbled 757.17% in 2021, then skyrocketed 65.96% in 2024.
  • Over 5 years, EBT stood at -$13.4 million in 2021, then fell by 19.75% to -$16.1 million in 2022, then rose by 26.81% to -$11.8 million in 2023, then crashed by 71.93% to -$20.2 million in 2024, then tumbled by 58.02% to -$31.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$31.9 million, -$24.3 million, and -$33.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.